Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.52 | 2.58 | 0.98 | 0.36 |
| FCF Yield | -0.79% | -1.12% | -0.42% | -5.02% |
| EV / EBITDA | 184.47 | -51.75 | -13.85 | -15.17 |
| Quality | ||||
| ROIC | -11.73% | -9.00% | -17.45% | -18.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.29 | 1.13 | 0.09 | 1.53 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 12.63% | -699.08% | 95.29% | 85.26% |
| Safety | ||||
| Net Debt / EBITDA | -5.95 | 7.42 | 5.15 | 2.72 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -154.20 | 0.00 | 0.00 |